What You Should Know:
- The Israel Innovation Authority announced today a NIS 113M ($31M USD) investment for the establishment of a center that will provide research and development (R&D) infrastructure for bio-devices based on bio-chips. The investment is part of the National Bio-Convergence Program.
- Bio-convergence represents the integration of biology and life sciences with engineering and software technologies. The investment is directed at companies dedicated to developing key service infrastructure for companies that develop bio-devices such as environmental diagnostic sensors, smart implants for treatment and diagnostics, lab-on-chip and organ-on-chip technologies.
Center for Bio-Chips-Based Bio-Devices
Bio-chips are revolutionary microdevices that combine biology, engineering, and microtechnology. These miniature chips integrate multiple laboratory functions onto a single platform, enabling efficient analysis of biological samples with minimal volumes. They offer precise fluid control and have transformed fields such as healthcare, diagnostics, and pharmaceutical research. Companies engaged in bio-devices based on bio-chips require knowledge in a wide range of sectors, which is very costly and thus a hindrance to the development process.
The goals of the new center include:
- Provision of cutting-edge R&D services to industry players and researchers involved in bio-device development using unique equipment and knowhow.
- Offering prototype production services and small-scale series production capabilities.
- Cultivation of advanced knowledge and the provision of applicable solutions that will enable international competitiveness for industrial corporations, research institutions, and other entities operating in the bio-convergence field.
- Training and human capital development to nurture a skilled workforce capable of delivering exceptional services to industrial corporations and research institutions.
